**Emerging Dosimeters and New QA Practices**

288 Modern Practices in Radiation Therapy

Steinman & Nussenzweig. (2002). Avoiding horror autotoxicus: the importance of dendritic

Sumida *et al.* (2004). Recruitment and expansion of dendritic cells in vivo potentiate the

Szlosarek & Balkwill. (2003). Tumour necrosis factor alpha: a potential target for the therapy

Taub *et al.* (1995). Alpha and beta chemokines induce NK cell migration and enhance NK-

Teitz-Tennenbaum *et al.* (2003). Radiotherapy potentiates the therapeutic efficacy of

Uchida *et al.* (1989). Effects of X-ray irradiation on natural killer (NK) cell system. II.

van Deventer *et al.* (2002). Transfection of macrophage inflammatory protein 1 alpha into

Vartak *et al.* (1993). Antitumor effects of local hyperthermia on a mouse fibrosarcoma.

Watters. (1999). Molecular mechanisms of ionizing radiation-induced apoptosis. *Immunol* 

Yasuda *et al.* (2011). Intratumoral injection of interleukin-2 augments the local and abscopal

Younes *et al.* (1995). Local tumor irradiation augments the response to IL-2 therapy in a

Younes *et al.* (1995). Radiation-induced effects on murine kidney tumor cells: role in the

Zhang *et al.* (2004). Mobilization of dendritic cell precursors into the circulation by

Zibert *et al.* (2004). CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with

effects of radiotherapy in murine rectal cancer. *Cancer Sci*, Vol.102, No.7, pp. 1257-

murine renal adenocarcinoma. *Cell Immunol*, Vol.165, No.2, pp. 243-251, ISSN 0008-

interaction of local irradiation and immunotherapy. *J Urol*, Vol.153, No.6, pp. 2029-

administration of MIP-1alpha in mice. *J Natl Cancer Inst*, Vol.96, No.3, pp. 201-209,

interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. *Hum Gene Ther*, Vol.15, No.1, pp. 21-34, ISSN 1043-

*Immunotoxicol*, Vol.11, No.2-3, pp. 521-534, ISSN 0892-3973 (Print)

*Anticancer Res*, Vol.13, No.3, pp. 727-729, ISSN 0250-7005 (Print)

*Cell Biol*, Vol.77, No.3, pp. 263-271, ISSN 0818-9641 (Print)

1263, ISSN 1349-7006 (Electronic) 1347-9032 (Linking)

358, ISSN 0027-8424 (Print) 0027-8424 (Linking)

1342, ISSN 0021-9738 (Print)

1470-2045 (Linking)

ISSN 0008-5472 (Print)

(Print)

8749 (Print)

0342 (Print)

2033, ISSN 0022-5347 (Print)

ISSN 1460-2105 (Electronic)

cells in peripheral T cell tolerance. *Proc Natl Acad Sci U S A*, Vol.99, No.1, pp. 351-

immunogenicity of plasmid DNA vaccines. *J Clin Invest*, Vol.114, No.9, pp. 1334-

of solid tumours. *Lancet Oncol*, Vol.4, No.9, pp. 565-573, ISSN 1470-2045 (Print)

mediated cytolysis. *J Immunol*, Vol.155, No.8, pp. 3877-3888, ISSN 0022-1767 (Print)

intratumoral dendritic cell administration. *Cancer Res*, Vol.63, No.23, pp. 8466-8475,

Increased sensitivity to natural killer cytotoxic factor (NKCF). *Immunopharmacol* 

B16 F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. *J Immunol*, Vol.169, No.3, pp. 1634-1639, ISSN 0022-1767

**16** 

 *USA* 

**Quality Assurance (QA) for Kilovoltage** 

Joerg Lehmann1,2 and Stanley Skubic2 *1 University of California Davis, Davis, CA,* 

*2Radiological Associates of Sacramento, Sacramento, CA,* 

 **Cone Beam Computed Tomography (CBCT)** 

The use of an imaging modality for verification of patient and target location immediately prior to application of radiation therapy has spread widely in the last years. It is referred to

Precise targeting of the tumor is very important and imaging can be immensely helpful in this process. Hence the quality assurance of the imaging systems used to guide the beam is also essential. One could argue that it is as critical as quality assurance for the radiation dose output, since the right amount of radiation dose delivered to the wrong location can be as

Kilovoltage (kV) Cone Beam Computed Tomography (CBCT) is a premiere modality for image guidance, since it produces three-dimensional images of the region of interest of the patient in a relatively short time (1-3 min) in a sufficient quality for the purpose of patient alignment. Popular systems are the Varian OBI (Varian Medical Systems, Inc., Palo Alto, CA, USA) and the Elekta XVI system (Elekta AB, Stockholm, Sweden), shown in

This chapter introduces the different tests needed for a comprehensive QA of kV CBCT. The tests are related to (1) System safety, (2) Geometric accuracy, that is agreement of the CBCT imaging isocenter with the isocenter of the MV treatment beam, (3) Registration and correction accuracy, that is how accurately can the system position a patient, (4) Image quality, and (5) x-ray tube and generator performance (dose to the patient). It further suggests a frequency with which each of the tests should be performed, organizing them in being part of the daily, monthly and annual QA procedures. In addition, tests which should

Responsibility for all tests should be with a Qualified Medical Physicist. Generally the physicist will delegate some of the tests, likely the daily tests to other members of the

For information about in-room kV X-ray imaging beyond CBCT QA see the report of AAPM

Radiation Therapy team, for instance the Radiation Therapists. (Klein et al., 2009).

detrimental as delivering the wrong amount of radiation dose to the right location.

be performed following system repair or upgrades are described.

Task Group 104 (Yin et al., 2009) and (Jaffrey et al., 1999).

**1. Introduction** 

figure 1.

as Image Guided Radiation Therapy (IGRT).
